The estimated Net Worth of Marc Schegerin is at least $5.26 million dollars as of 8 July 2024. Dr Schegerin owns over 43,936 units of Morphic Inc stock worth over $4,664,233 and over the last 5 years he sold MORF stock worth over $0. In addition, he makes $597,088 as CFO & COO at Morphic Inc.
Dr has made over 12 trades of the Morphic Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 43,936 units of MORF stock worth $659,040 on 8 July 2024.
The largest trade he's ever made was exercising 56,666 units of Morphic Inc stock on 7 March 2023 worth over $849,990. On average, Dr trades about 12,587 units every 89 days since 2019. As of 8 July 2024 he still owns at least 81,843 units of Morphic Inc stock.
You can see the complete history of Dr Schegerin stock trades at the bottom of the page.
Dr. Marc Schegerin M.B.A., M.D. is the CFO & COO at Morphic Inc.
As the CFO & COO of Morphic Inc, the total compensation of Dr D at Morphic Inc is $597,088. There are 5 executives at Morphic Inc getting paid more, with Timothy Springer having the highest compensation of $1,260,500.
Dr D is 45, he's been the CFO & COO of Morphic Inc since . There are 16 older and 3 younger executives at Morphic Inc. The oldest executive at Morphic Holding Inc is Dr. Timothy A. Springer Ph.D., 73, who is the Founder, Independent Director & Member of Scientific Advisory Board.
Marc's mailing address filed with the SEC is C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM, MA, 02451.
Over the last 5 years, insiders at Morphic Inc have traded over $69,316,197 worth of Morphic Inc stock and bought 3,360,997 units worth $101,882,696 . The most active insiders traders include Plc Gsk, Holdings A/S Novo et Timothy A Springer. On average, Morphic Inc executives and independent directors trade stock every 13 days with the average trade being worth of $2,254,353. The most recent stock trade was executed by Bruce Rogers on 8 July 2024, trading 20,000 units of MORF stock currently worth $86,400.
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Morphic Inc executives and other stock owners filed with the SEC include: